Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MSB Mesabi

Market Closed 12-12 16:00:00 EST

34.63

-0.69

-1.95%

盘后34.63

+0.000.00%

16:10 EST

High35.56	Low34.63	Vol17.33K
Open34.86	D1 Closing35.32	Amplitude2.63%
Mkt Cap454.35M	Tradable Cap454.00M	Total Shares13.12M
T/O607.25K	T/O Rate0.13%	Tradable Shares13.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MSB","market":"US","secType":"STK","nameCN":"Mesabi","latestPrice":34.63,"timestamp":1765573200000,"preClose":35.32,"halted":0,"volume":17327,"hourTrading":{"tag":"盘后","latestPrice":34.63,"preClose":34.63,"latestTime":"16:10 EST","volume":221,"amount":7653.23,"timestamp":1765573803688},"delay":0,"floatShares":13109915,"shares":13120010,"eps":7.0707,"marketStatus":"Market Closed","change":-0.69,"latestTime":"12-12 16:00:00 EST","open":34.86,"high":35.56,"low":34.63,"amount":607250.4696,"amplitude":0.026331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.0707,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":35.32,"dividendRate":0.202714,"postHourTrading":{"tag":"盘后","latestPrice":34.63,"preClose":34.63,"latestTime":"16:10 EST","volume":221,"amount":7653.23,"timestamp":1765573803688},"volumeRatio":0.4743302665235789,"impliedVol":0.2001,"impliedVolPercentile":0.052},"requestUrl":"/m/hq/s/MSB/tweets","defaultTab":"tweets","newsList":[{"id":"2590547736","title":"Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547736?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495320,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent pe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204384/0/en/Independent-Study-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting-Concludes-Remestemcel-L-Superior-to-Ruxolitinib-in-Clinical-Outcomes-as-Treatment-for-SR-aGvHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4107","BK4117","BK4139","BK4150","MSC","LU2463526074.USD","MSB","BK4109","ASH","AFG","SPN","BK4575","MESO","SR","BK4197"],"gpt_icon":0},{"id":"2590541654","title":"Is Mesoblast (ASX:MSB) Using High-Profile Conferences To Recast Its Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541654","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541654?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:33","pubTimestamp":1765463582,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently presented at the Piper Sandler 37th Annual Healthcare Conference in New York, led by Founder and CEO Silviu Itescu.\nThe CEO’s direct participation in this high-profile healthcare forum positioned Mesoblast to highlight its scientific direction, clinical priorities, and broader corporate story to an influential audience.\nWe’ll now examine how Mesoblast’s high-profile conference appearance with direct CEO participation may influence the company’s broader investment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","MSB.AU","BK7501","MSB","BK7067","BK7508"],"gpt_icon":0},{"id":"2590574534","title":"Mesoblast (ASX:MSB) Valuation Check as Investors Eye Piper Sandler Healthcare Conference Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590574534?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:27","pubTimestamp":1765373230,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) steps into the spotlight this week as CEO Silviu Itescu presents at the Piper Sandler 37th Annual Healthcare Conference, and traders are watching for fresh color on strategy and late stage trials.\nSee our latest analysis for Mesoblast.\nThat anticipation has arrived on the back of a strong near term rebound, with a 1 month share price return of 27.03 percent and a 1 year total shareholder return of 65.88 percent, even though the year to date share price return remains...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","MSB.AU","BK7508","XLV","BK4137","LABU","HCSG","XBI","BK4006","LU0128526141.USD","BK4211","BK4585","LU0029874061.USD","BK4588","MSB","ISBC","DCF","BK4581"],"gpt_icon":0},{"id":"2590041013","title":"Matrixport Appoints Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590041013","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590041013?lang=en_us&edition=fundamental","pubTime":"2025-12-10 16:00","pubTimestamp":1765353600,"startTime":"0","endTime":"0","summary":"Seasoned finance leader to drive company's next phase of growth and innovation. ZURICH, Dec. 10, 2025 /PRNewswire/ -- Matrixport Groupis pleased to announce the appointment of Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG, effective today.\"With our Swiss asset management platform in place, Matrixport Asset Management is entering its next phase focused on scaling an institution-grade business across Europe. Dominik's appointment reflects our priorities in strengthening investment capabilities and building a long-term presence in key European markets.\" said John Ge, CEO of Matrixport Group.\"I am honored to join Matrixport Asset Management AG as CEO and I look forward to working with the talented team. Being part of Matrixport Group, a global digital asset player in Asia, I am convinced we can deliver innovative investment solutions, strengthen client relationships, and expand Matrixport Group's presence in both traditional and digital asset markets in Swi","market":"us","thumbnail":"https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/matrixport-appoints-dominik-oggenfuss-as-chief-executive-officer-of-matrixport-asset-management-ag-302637423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","AG","MSB","BK4210","MSB.AU","BK7508","BK7067","BK4006"],"gpt_icon":0},{"id":"2588020600","title":"Mesoblast Participation at Piper Sandler Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588020600","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588020600?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199432/0/en/Mesoblast-Participation-at-Piper-Sandler-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4139","BK4150","MSC","MSB","BK4575","MESO"],"gpt_icon":0},{"id":"2587754974","title":"Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587754974","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587754974?lang=en_us&edition=fundamental","pubTime":"2025-11-29 09:23","pubTimestamp":1764379395,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease.\nThis combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB"],"gpt_icon":0},{"id":"2586248870","title":"A Look at Mesoblast (ASX:MSB) Valuation as New Ryoncil Sales Forecast and Pivotal Trial Spark Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248870","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586248870?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:37","pubTimestamp":1764221823,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has caught the market's attention with a new revenue forecast for December 2025, expecting sales of Ryoncil to top $30 million, an increase of 37% from the previous quarter. The company also announced a collaboration to launch a pivotal trial that could expand Ryoncil’s use in adults with severe graft versus host disease.\nSee our latest analysis for Mesoblast.\nMesoblast’s upbeat revenue guidance and new clinical trial plans have reinvigorated investor sentiment, reflected...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblast-asxmsb-valuation-as-new-ryoncil-sales-fo","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblast-asxmsb-valuation-as-new-ryoncil-sales-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB"],"gpt_icon":0},{"id":"2585417117","title":"How a Seasoned CFO Appointment Could Shape Mesoblast's (ASX:MSB) Commercial Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585417117","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585417117?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:18","pubTimestamp":1763713089,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently announced the appointment of James M. O’Brien as its new US-based Chief Financial Officer, drawing on his extensive financial leadership across global life sciences, biotechnology, and pharmaceutical companies.\nO’Brien’s expertise in orchestrating large-scale corporate transactions and public offerings brings significant operational and financial acumen to Mesoblast's transition into a fully integrated commercial organization.\nWe’ll now explore how the addition of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MSB.AU","BK4006","BK7067","BK7501","MSB"],"gpt_icon":0},{"id":"2585166564","title":"Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166564","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166564?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:32","pubTimestamp":1763681520,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high ra","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192470/0/en/Mesoblast-and-BMT-CTN-to-Initiate-Pivotal-Trial-of-Ryoncil-as-Part-of-First-Line-Regimen-in-Adults-with-Severe-Acute-GVHD-Refractory-to-Steroids.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4192","MSB","BK4139","MESO","BK4150","BK4535","BK4575","MCW","MSC","BK4539"],"gpt_icon":0},{"id":"2584464645","title":"iFAST vs SGX: Which Growth Stock Could Deliver Better Returns in 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584464645","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584464645?lang=en_us&edition=fundamental","pubTime":"2025-11-17 17:30","pubTimestamp":1763371800,"startTime":"0","endTime":"0","summary":"Which growth stock stands to achieve better returns in 2026?","market":"sg","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/iFAST-vs-SGX-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/iFAST-vs-SGX-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/ifast-vs-sgx-which-growth-stock-could-deliver-better-returns-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/ifast-vs-sgx-which-growth-stock-could-deliver-better-returns-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK4143","LU2401740654.USD","LU1920062954.HKD","SG9999004360.SGD","BK6523","LU0898667661.SGD","SG9999014484.SGD","BK6516","SG9999001846.SGD","SG9999000343.SGD","SG9999013478.USD","SGXZ58947870.SGD","LU0877626530.USD","LU2242646235.USD","LU0831103253.SGD","AIY.SI","SG9999016042.SGD","SG9999003826.SGD","SG9999006266.SGD","LU2242646821.SGD","LU0188438112.USD","BK4006","LU0205439572.USD","SGXZ27511609.SGD","SG9999013460.SGD","IE00BKZH1Z71.USD","BK6052","S68.SI","BK6503","LU1920063259.USD","SG9999014492.USD","SG9999001135.SGD","LU0441851309.USD","MSB","CIX","LU0192582467.USD","LU1119993845.HKD","SG9999013486.USD","LU0326948709.USD","LU1839390173.USD","BK6033","LU0532188223.SGD","LU2242652126.USD"],"gpt_icon":0},{"id":"2584737614","title":"Press Release: James M. O'Brien Appointed Chief Financial Officer at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2584737614","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584737614?lang=en_us&edition=fundamental","pubTime":"2025-11-17 14:52","pubTimestamp":1763362320,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 17, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed James M. O'Brien as its US-based Chief Financial Officer . Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant red","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4150","MSB.AU","CFO","MSB","BK4006","BK4575","BK7501","MSC","BMS","BK4022","BK4232","MESO","BK7508","BK4139","R","BK7067"],"gpt_icon":0},{"id":"2584869657","title":"Mesoblast (ASX:MSB) Valuation Spotlight as FDA Reviews Opioid-Reducing Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2584869657","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584869657?lang=en_us&edition=fundamental","pubTime":"2025-11-17 00:15","pubTimestamp":1763309724,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) revealed that the US FDA will convene in December to review data from its Phase 3 trial on rexlemestrocel-L. The focus will be on opioid reduction in chronic low back pain patients. This closely follows updated FDA guidance prioritizing non-opioid therapies in response to the ongoing opioid crisis.\nSee our latest analysis for Mesoblast.\nMesoblast shares have seen sharp swings this year, with the latest price at $2.22 and a 30-day share price return of -20.71% reflecting...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-spotlight-as-fda-reviews-opioid-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-spotlight-as-fda-reviews-opioid-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7067","BK7501","MSB.AU","MSB","BK4006","DCF"],"gpt_icon":0},{"id":"2582223243","title":"FDA Review of Opioid-Reduction Data Could Be a Game Changer for Mesoblast (ASX:MSB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582223243","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582223243?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:28","pubTimestamp":1762939694,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently announced that the U.S. FDA has scheduled a December meeting to review Phase 3 data on opioid reduction and cessation for its investigational therapy rexlemestrocel-L in patients with chronic low back pain (CLBP), following a trial showing higher opioid cessation rates compared to controls.\nThis FDA engagement comes amid new guidance promoting non-opioid pain treatments, highlighting the therapy's potential role in addressing the U.S. opioid crisis.\nWe'll explore...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/fda-review-of-opioid-reduction-data-could-be-a-game-changer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/fda-review-of-opioid-reduction-data-could-be-a-game-changer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK4006","BK7508","MSB.AU","BK7067","MSB"],"gpt_icon":0},{"id":"2581279620","title":"Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279620","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581279620?lang=en_us&edition=fundamental","pubTime":"2025-11-05 07:40","pubTimestamp":1762299600,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  04, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3181021/0/en/Mesoblast-to-Meet-With-FDA-Next-Month-to-Discuss-Rexlemestrocel-L-and-Opioid-Cessation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4170","BK4588","BK4139","BK4150","BK4546","MESO","MSC","MSB","BK4161","BK4006","DDD","BK4551","BK4585"],"gpt_icon":0},{"id":"2577533166","title":"Nyse Order Imbalance  11228.0 Shares on Buy Side","url":"https://stock-news.laohu8.com/highlight/detail?id=2577533166","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577533166?lang=en_us&edition=fundamental","pubTime":"2025-10-24 03:50","pubTimestamp":1761249005,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nAQN2L4FY1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4006","MSB"],"gpt_icon":0},{"id":"2577378239","title":"Mr. Beast's Financial Gamble","url":"https://stock-news.laohu8.com/highlight/detail?id=2577378239","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577378239?lang=en_us&edition=fundamental","pubTime":"2025-10-23 15:15","pubTimestamp":1761203700,"startTime":"0","endTime":"0","summary":"In October 2025, MrBeast submitted a trademark application to the United States Patent and Trademark Office for \"MrBeast Financial.\"This 27-year-old individual, who in the real world has buried himsel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"theblockbeats_highlight","url":"https://www.theblockbeats.info/en/news/59978","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/59978","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["BK4006","MSB"],"gpt_icon":0},{"id":"2577842033","title":"Mesoblast (ASX:MSB) Valuation in Focus After Rising Ryoncil® Revenues and New US Reimbursement Pathways","url":"https://stock-news.laohu8.com/highlight/detail?id=2577842033","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577842033?lang=en_us&edition=fundamental","pubTime":"2025-10-21 12:33","pubTimestamp":1761021190,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is catching investor attention following its announcement that Ryoncil® revenues are on the rise. This growth is supported by expanding physician adoption and access through both commercial and government reimbursement programs.\nSee our latest analysis for Mesoblast.\nWith momentum building off the back of Ryoncil®’s revenue growth and new CMS reimbursement pathways, Mesoblast’s share price has rebounded 16.7% over the past three months. But the real highlight is the 82.2%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-rising-ryoncil-rev","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-rising-ryoncil-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","MSB.AU"],"gpt_icon":0},{"id":"2576630028","title":"Mesabi Trust Up Nearly 14%, on Track for Highest Close Since October 2021 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2576630028","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576630028?lang=en_us&edition=fundamental","pubTime":"2025-10-20 22:58","pubTimestamp":1760972280,"startTime":"0","endTime":"0","summary":"Mesabi Trust  is currently at $35.60, up $4.35 or 13.9%. --Would be highest close since Oct. 21, 2021, when it closed at $35.96. --On pace for largest percent increase since Sept. 11, 2024, when it rose 23.93%. --Currently up two consecutive days; up 15.98% over this period. --Best two-day stretch since the two days ending Feb. 20, 2025, when it rose 22.72%. --Down 36.93% from its all-time closing high of $56.44 on Dec. 13, 2010. --Up 41.53% from 52 weeks ago , when it closed at $25.15. --Up 56.6% from its 52-week closing low of $22.73 on June 25, 2025. --Traded as high as $36.59; highest intraday level since Jan. 28, 2025, when it hit $37.00. --Up 17.1% at today's intraday high; largest intraday percent increase since Sept. 11, 2024, when it rose as much as 33.59%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB","BK4006"],"gpt_icon":0},{"id":"2575735865","title":"Mesoblast (ASX:MSB) J-Code for Ryoncil Secures Reimbursement Access Is the Commercial Strategy Evolving?","url":"https://stock-news.laohu8.com/highlight/detail?id=2575735865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575735865?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:27","pubTimestamp":1760527671,"startTime":"0","endTime":"0","summary":"On October 1, 2025, Mesoblast Limited announced that a permanent Medicare HCPCS J-Code (J3402) for Ryoncil® (remestemcel-L-rknd) became active, providing a standardized billing pathway for this FDA-approved therapy in pediatric steroid-refractory acute graft-versus-host disease.\nThis CMS formal recognition is expected to simplify reimbursement and potentially broaden both public and private payer access to the only mesenchymal stromal cell product approved for children under age 12 with this...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-j-code-for-ryoncil-secures-reimbursement-ac","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-j-code-for-ryoncil-secures-reimbursement-ac","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4006","BK7501","BK7508","MSB","BK7067"],"gpt_icon":0},{"id":"2574307496","title":"Mesoblast (ASX:MSB) Valuation in Focus After Ryoncil Secures U.S. Reimbursement Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2574307496","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574307496?lang=en_us&edition=fundamental","pubTime":"2025-10-12 09:24","pubTimestamp":1760232243,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) shares have drawn attention after the company announced that its Ryoncil therapy received a permanent J-Code from U.S. Centers for Medicare & Medicaid Services, effective October 1. This update simplifies reimbursement and billing for providers.\nSee our latest analysis for Mesoblast.\nMesoblast’s latest breakthrough with Ryoncil arrives as investor optimism has been building steadily. After lagging earlier in the year, the share price has surged 75% in the past three...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-secures-us","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-after-ryoncil-secures-us","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","BK7067","BK7501","BK4006","DCF","MSB.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesabi-trust.com","stockEarnings":[{"period":"1week","weight":0.0519},{"period":"1month","weight":-0.0072},{"period":"3month","weight":0.1015},{"period":"6month","weight":0.3475},{"period":"1year","weight":0.3157},{"period":"ytd","weight":0.2319}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was founded in 1961 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.577778,"avgChangeRate":0.06447},{"month":2,"riseRate":0.577778,"avgChangeRate":0.033796},{"month":3,"riseRate":0.4,"avgChangeRate":0.011105},{"month":4,"riseRate":0.391304,"avgChangeRate":-0.003842},{"month":5,"riseRate":0.521739,"avgChangeRate":0.010145},{"month":6,"riseRate":0.369565,"avgChangeRate":-0.009375},{"month":7,"riseRate":0.347826,"avgChangeRate":-0.009187},{"month":8,"riseRate":0.413043,"avgChangeRate":0.000339},{"month":9,"riseRate":0.413043,"avgChangeRate":0.003772},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.005844},{"month":11,"riseRate":0.478261,"avgChangeRate":-0.001259},{"month":12,"riseRate":0.434783,"avgChangeRate":0.023318}],"exchange":"NYSE","name":"Mesabi","nameEN":"Mesabi"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesabi,MSB,Mesabi股票,Mesabi股票老虎,Mesabi股票老虎国际,Mesabi行情,Mesabi股票行情,Mesabi股价,Mesabi股市,Mesabi股票价格,Mesabi股票交易,Mesabi股票购买,Mesabi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction